Pacira BioSciences Inc
(NAS:PCRX)
$
16.81
-0.7 (-4%)
Market Cap: 776.17 Mil
Enterprise Value: 998.18 Mil
PE Ratio: 0
PB Ratio: 1.03
GF Score: 72/100 Pacira Biosciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019 / 10:00PM GMT
Release Date Price:
$46.59
(-0.66%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP
Good afternoon. Thanks for joining us. I'm Tazeen Ahmad. I'm the senior biotech analyst here at Bank of America Merrill Lynch. It's my pleasure to introduce our next presenting company, Pacira BioSciences. Sitting next to me is CEO, Dave Stack; and sitting next to him is CFO, Charlie Reinhart. Thanks, guys, for joining us.
David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO
Thank you.
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP
So the format today is going to be Q&A, but I think for the benefit of everyone in the audience, maybe, Dave, you can give us a 2-minute introduction to Pacira and tell us what's been going on with the company, and then we can go from there.
David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO
Sure. It's -- well, we're off to a good start. I mean things are good at Pacira. I think the best visibility, I think, I can give to anybody that's listening is the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot